IntelGenx Technologies Corp.
OTCQX : IGXT
TSX VENTURE : IGX

IntelGenx Technologies Corp.

August 02, 2016 09:17 ET

IntelGenx to Report Second Quarter 2016 Financial Results on August 11, 2016

SAINT-LAURENT, CANADA--(Marketwired - Aug. 2, 2016) - IntelGenx Technologies Corp., (TSX VENTURE:IGX)(OTCQX:IGXT), today announced that it will release its second quarter 2016 results for the period ended June 30, 2016, on August 11, 2016 at the close of the financial markets.

An accompanying conference call will be hosted by Dr. Horst G. Zerbe, President and Chief Executive Officer and Mr. Andre Godin, Executive Vice-President and Chief Financial Officer, to discuss the results and provide a business update. Details of the conference call and webcast are below:

Date: Thursday, August 11, 2016

Time: 4:30 p.m. ET

Conference dial-in: (877) 201-0168

Conference ID: 47950179

International dial-in: (647) 788-4901

Webcast Registration: Click Here

Following the live call, a replay will be available on the Company's website, www.intelgenx.com, under "Investor Relations".

About IntelGenx:

IntelGenx is a leading drug delivery company focused on the development of innovative products based on its proprietary oral drug delivery technologies.

Established in 2003, the Montreal-based company, listed on the TSX-V and OTC-QX, develops innovative oral drug delivery solutions based on its proprietary platform technologies, VersaFilm™, VersaTab™ and AdVersa™.

IntelGenx has developed a broad and diverse product portfolio addressing unmet market needs and offering lifecycle management opportunities. Forfivo XL™, launched in 2012, is the first and only FDA approved once-daily bupropion HCl 450mg dose in a single tablet for the treatment of major depressive disorder.

IntelGenx highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, clinical monitoring, IP protection, analytical method development and regulatory services. IntelGenx state-of-the art manufacturing facility, established for the VersaFilm™ technology platform, supports lab-scale to pilot and commercial-scale production, offering full service capabilities to our clients. More information is available about the company at: www.intelgenx.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange), nor the OTCQX accepts responsibility for the adequacy or accuracy of this release.

Source: IntelGenx Technologies Corp.

Contact Information

  • Edward Miller
    Director, IR and Corporate Communications
    IntelGenx Corp.
    +1 514-331-7440 (ext. 217)
    edward@intelgenx.com